The health technology assessment agency has recommended that the drug be used on the NHS to treat CKD in adults if it is an add-on to optimised standard care, including the highest tolerated licensed dose of angiotensin-converting enzyme inhibitors and angiotensin-2 receptor antagonists, unless these are contraindicated.
Eligible patients must either have an estimated glomerular filtration rate (eGFR) of 20 ml/min/1.73m2 to less than 45ml/min/1.73 m2, or an eGFR of 45ml/min/1.73m2 to 90 ml/min/1.73m2 and have a urine albumin-to-creatine ratio of at least 22.6mg/mmol or type 2 diabetes…
